BRPI0417248A - métodos de preparação de compostos utilizáveis como inibidores de protease - Google Patents

métodos de preparação de compostos utilizáveis como inibidores de protease

Info

Publication number
BRPI0417248A
BRPI0417248A BRPI0417248-5A BRPI0417248A BRPI0417248A BR PI0417248 A BRPI0417248 A BR PI0417248A BR PI0417248 A BRPI0417248 A BR PI0417248A BR PI0417248 A BRPI0417248 A BR PI0417248A
Authority
BR
Brazil
Prior art keywords
methods
protease inhibitors
preparing compounds
compounds usable
usable
Prior art date
Application number
BRPI0417248-5A
Other languages
English (en)
Inventor
David John Kucera
Nabil Lauze Saeed
Robert William Scott
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0417248A publication Critical patent/BRPI0417248A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"MéTODOS DE PREPARAçãO DE COMPOSTOS UTILIZáVEIS COMO INIBIDORES DE PROTEASE". A presente invenção refere-se a métodos de preparação de compostos de fórmula (I) que são utilizáveis como inibidores da enzima protease de HIV. A presente invenção também refere-se a compostos intermediários utilizáveis na preparação de compostos de fórmula (I).
BRPI0417248-5A 2003-12-04 2004-11-22 métodos de preparação de compostos utilizáveis como inibidores de protease BRPI0417248A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52747003P 2003-12-04 2003-12-04
US59135404P 2004-07-26 2004-07-26
PCT/IB2004/003810 WO2005054187A1 (en) 2003-12-04 2004-11-22 Methods of preparing compounds useful as protease inhibitors

Publications (1)

Publication Number Publication Date
BRPI0417248A true BRPI0417248A (pt) 2007-03-06

Family

ID=34657228

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417248-5A BRPI0417248A (pt) 2003-12-04 2004-11-22 métodos de preparação de compostos utilizáveis como inibidores de protease

Country Status (10)

Country Link
US (1) US20050153903A1 (pt)
EP (1) EP1692104A1 (pt)
JP (1) JP2007513140A (pt)
KR (1) KR20060097047A (pt)
AU (1) AU2004295186A1 (pt)
BR (1) BRPI0417248A (pt)
CA (1) CA2547955A1 (pt)
IL (1) IL175528A0 (pt)
NO (1) NO20062041L (pt)
WO (1) WO2005054187A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2002000136A (es) * 2001-06-11 2003-07-31 Basf Ag Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
JP2006288864A (ja) * 2005-04-13 2006-10-26 Padoru:Kk 外科手術用の骨固定具
CA3174069A1 (en) 2020-03-06 2021-09-10 Pfizer Inc. Methods of inhibiting sars-cov-2 replication and treating coronavirus disease 2019

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313094B1 (en) * 1990-12-11 2001-11-06 Japan Energy Corporation β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors
US5644028A (en) * 1992-05-13 1997-07-01 Japan Energy Corporation Process for producing peptide derivatives and salts therefor
ZA935697B (en) * 1992-08-07 1994-03-10 Sankyo Co Peptides capable of inhibiting the activity of hiv protease their preparation and their therapeutic use
CA2179935C (en) * 1995-06-30 2010-09-07 Ryohei Kato Novel dipeptide compound or pharmaceutically acceptable salt thereof and medical use thereof
US6222043B1 (en) * 1995-06-30 2001-04-24 Japan Energy Corporation Methods of preparing novel dipeptide compounds or pharmaceutically acceptable salts thereof
US6673772B2 (en) * 1999-01-14 2004-01-06 Sumitomo Pharmaceuticals Company Limited Dipeptide compounds and their use as antiviral agents
HN2002000136A (es) * 2001-06-11 2003-07-31 Basf Ag Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
US7094909B2 (en) * 2001-06-11 2006-08-22 Agouron Pharmaceuticals, Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis

Also Published As

Publication number Publication date
AU2004295186A1 (en) 2005-06-16
KR20060097047A (ko) 2006-09-13
CA2547955A1 (en) 2005-06-16
IL175528A0 (en) 2006-09-05
EP1692104A1 (en) 2006-08-23
WO2005054187A1 (en) 2005-06-16
JP2007513140A (ja) 2007-05-24
NO20062041L (no) 2006-06-01
US20050153903A1 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
BR0307960A (pt) N-aminoacetil-pirrolidina-2-carbonitrilas e seu uso como inibidores de ddp-iv
BRPI0413973A (pt) compostos
BRPI0518758A2 (pt) compostos de acetamida como fungicidas
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
TNSN08024A1 (en) 7-substituted aza-indazoles, compositions containing same, production method and use thereof
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
HRP20070043A2 (en) Antiviral compounds
MA30531B1 (fr) Anticorps anti-dll4 et leurs procedes d'utilisation
BR0316470A (pt) Derivados de 3-amino-piperadina e métodos de preparação
BR0114252A (pt) Derivados de nitrosodifenilamina
NZ580226A (en) Dimer compounds as inhibitors of iap
ECSP067110A (es) Derivados de 2-carbamida-4-feniltiazol, su preparación y su aplicación en terapéutica
BRPI0517999A (pt) derivados de tetraidropirano como antidiabéticos
CR9463A (es) Pirrolinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion
NO20071880L (no) Diagnostic Compounds
BR0308211A (pt) Cumarinas úteis como biomarcadores
GT200200069A (es) Derivados de mercaptoacetilamida, procedimiento para su preparacion y su uso
ECSP088252A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
ATE485261T1 (de) Salicylsäurederivate
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina
CR9182A (es) Derivado de quinolina, su uso, preparacion y medicamento que lo contiene
BRPI0606639A2 (pt) novo processo para a preparação de indóis substituìdos
UY29892A1 (es) Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
PL1831239T3 (pl) Sposób wytwarzania gamma-laktonu kwasu 17-hydroksy-6 beta, 7 beta,15 beta, 16 beta-bismetyleno-17 alpha-pregn-4-en-3-ono-21-karboksylowego i związki pośrednie kluczowe dla tego sposobu
BR0212535A (pt) Compostos e composições como inibidores de catepsina

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]